The Blacklisting of Peptides FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 (compounding only, no legal prescribing) into Category 1. This means When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions